# TroFuse-031 (NCT07419295)

> A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

No report yet. It can be ordered.

- Drugs tested: sacituzumab tirumotecan
- Indication: pretreated locally advanced/metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07419295
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Bladder Cancer
- Interventions: Sacituzumab tirumotecan; Vinflunine; Docetaxel; Paclitaxel; Rescue medications for sacituzumab tirumotecan; Rescue medications for chemotherapy
- Enrollment: 590
- Primary outcome: Overall Survival (OS)

## Indexed commentary on TroFuse-031 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=trofuse-031-nct07419295
